68Ga Prostate-specific Membrane Antigen Uptake in Metastatic Medullary Thyroid Carcinoma

---

Şahin K., Kibar A., Güneren C., Sağer M. S., Sönmezoğlu K.

MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, sa.1, ss.54-56, 2024 (ESCI, TRDizin)

• Yayın Türü: Makale / Tam Makale
• Basım Tarihi: 2024
• Doi Numarası: 10.4274/mirt.galenos.2023.47855
• Dergi Adı: MOLECULAR IMAGING AND RADIONUCLIDE THERAPY
• Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
• Sayfa Sayıları: ss.54-56
• İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

We present the case of a 58-year-old man with advanced medullary thyroid carcinoma who had a treatment history with different types of modalities. In the follow-up, the patient had rising calcitonin and CEA levels. Metastatic lymph nodes, liver, and bone metastases with varying degrees of uptake were detected on 18F-fluorodeoxyglucose (FDG) and 68Ga-DOTATATE positron emission tomography/computed tomography (PET/CT). 68Ga prostate-specific membrane antigen (PSMA) PET/CT was performed to explore whether the patient might have a chance for PSMAtargeted radionuclide therapy, and increased PSMA expression was noted in most of the metastatic lesions, even some of which have higher PSMA uptake than 18F-FDG and 68Ga-DOTATATE.